U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07227818) titled 'Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia' on Nov. 11.
Brief Summary: The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Schizophrenia
Intervention:
DRUG: NBI-1117568
Oral capsules
DRUG: Placebo
Oral capsules
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Neurocrine Biosciences
Published by HT Digital Content Services with permission from Health Daily Digest....